InhalPlus develops a patented inhalation system to improve respiratory therapy in preterm infants.
InhalPlus has raised $560K in total funding. The most recent round was Pre-Seed. The last funding was announced in October 2026.
InhalPlus's investors include NBank Capital.
InhalPlus is headquartered in Hanover, Germany.
InhalPlus develops a patented inhalation system to improve respiratory therapy in preterm infants.
InhalPlus is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"InhalPlus — Funding & Investors." VCBacked, October 26, 2026, https://www.vcbacked.co/company/inhalplus. Accessed November 4, 2026.
VCBacked. (2026). InhalPlus — Funding & Investors. Retrieved November 4, 2026, from https://www.vcbacked.co/company/inhalplus
{{cite web |title=InhalPlus — Funding & Investors |url=https://www.vcbacked.co/company/inhalplus |website=VCBacked |access-date=November 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at InhalPlus? Request a listing update